Status:
COMPLETED
Insulin Glargine in Type 2 Diabetes
Lead Sponsor:
Sanofi
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The aim of this project is to confirm the efficacy and safety profile of Insulin glargine in daily practice and to improve the physicians' knowledge and experience concerning Insulin glargine
Eligibility Criteria
Inclusion
- Type 2 Diabetes Mellitus patients,
- Diabetic patients receiving insulin or patients who are insulin-naive and whose glycemic control cannot be sufficiently maintained with single or combined oral antidiabetic agents,
- Patients with HbA1C\>8
- Patients able to self-measure its blood glucose levels.
Exclusion
- According to package insert information (Summary of Product Characteristics)
Key Trial Info
Start Date :
September 1 2004
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
534 Patients enrolled
Trial Details
Trial ID
NCT00268645
Start Date
September 1 2004
Last Update
January 11 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sanofi-Aventis
Istanbul, Turkey (Türkiye)